论文部分内容阅读
目的观察曲妥珠单抗联合多西紫杉醇对Her-2/neu高表达的局部晚期乳腺癌新辅助化疗的疗效。方法 16例Her-2/neu高表达的局部晚期乳腺癌患者接受曲妥珠单抗联合多西紫杉醇的方案治疗。曲妥珠单抗的首次剂量为4mg/kg,以后剂量为2mg/kg,每7d一次。多西紫杉醇75mg/m2,每21d重复一次。按WHO疗效评价标准评价疗效,按WHO化疗药物急性和亚急性不良反应评价标准评价不良反应。结果全组16例患者术前共完成68次新辅助化疗(范围4～6次),所有患者均可评价疗效。16例患者中完全缓解4例,部分缓解10例,病情稳定2例,客观有效率(CR+PR)87.5%。全组均可评价不良反应,主要不良反应为骨髓抑制,其中Ⅲ～Ⅳ度白细胞减少发生率为62.5%,部分患者有轻度的心肌劳损。结论曲妥珠单抗联合多西紫杉醇对Her-2/neu高表达的局部晚期乳腺癌新辅助化疗的疗效较高,不良反应轻,患者可以耐受。
Objective To observe the effect of trastuzumab combined with docetaxel on neoadjuvant chemotherapy in locally advanced breast cancer with Her-2 / neu overexpression. Methods Sixteen patients with locally advanced breast cancer with Her-2 / neu overexpression were treated with trastuzumab combined with docetaxel. The first dose of trastuzumab was 4 mg / kg and the subsequent dose was 2 mg / kg once every 7 days. Docetaxel 75mg / m2, repeated every 21d. According to WHO evaluation criteria for the evaluation of the efficacy of the WHO chemotherapy drugs acute and subacute adverse reactions evaluation criteria for evaluation of adverse reactions. Results A total of 68 neoadjuvant chemotherapies (range 4 to 6) were performed in the 16 patients before the operation. All patients were evaluated for their efficacy. Among the 16 patients, 4 were completely relieved, 10 were partly relieved, 2 were stable, and the objective response rate (CR + PR) was 87.5%. The whole group can be evaluated adverse reactions, the main adverse reactions of bone marrow suppression, in which Ⅲ ~ Ⅳ leukopenia incidence was 62.5%, some patients with mild myocardial strain. Conclusions Trastuzumab combined with docetaxel has a higher therapeutic effect on neoadjuvant chemotherapy of locally advanced breast cancer with high expression of Her-2 / neu. The adverse reactions are mild and patients can tolerate.